Last reviewed · How we verify

COVID-19 prevention in individuals 5 years of age and older — Treatment Landscape & Competitive Intelligence

COVID-19 prevention in individuals 5 years of age and older (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating COVID-19 prevention in individuals 5 years of age and older, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
bivalent BNT162b2 (original/Omi BA.4/BA.5) bivalent-bnt162b2-original-omi-ba-4-ba-5 Pfizer mRNA vaccine SARS-CoV-2 virus
BNT162b6 Bivalent (Original/OMI BA.4/BA.5) bnt162b6-bivalent-original-omi-ba-4-ba-5 Pfizer vaccine SARS-CoV-2 spike protein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in COVID-19 prevention in individuals 5 years of age and older

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in COVID-19 prevention in individuals 5 years of age and older:

Cite this brief

Drug Landscape (2026). COVID-19 prevention in individuals 5 years of age and older — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing